1. Home
  2. TRNS vs OMER Comparison

TRNS vs OMER Comparison

Compare TRNS & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Transcat Inc.

TRNS

Transcat Inc.

HOLD

Current Price

$88.86

Market Cap

861.5M

Sector

Industrials

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$9.27

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRNS
OMER
Founded
1964
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
861.5M
772.8M
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
TRNS
OMER
Price
$88.86
$9.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$116.00
$32.50
AVG Volume (30 Days)
178.4K
2.3M
Earning Date
05-18-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.15
EPS
0.57
0.62
Revenue
$331,877,000.00
$29,868,000.00
Revenue This Year
$21.75
N/A
Revenue Next Year
$7.55
$233.22
P/E Ratio
$156.19
$14.97
Revenue Growth
19.20
N/A
52 Week Low
$50.23
$3.34
52 Week High
$94.76
$17.65

Technical Indicators

Market Signals
Indicator
TRNS
OMER
Relative Strength Index (RSI) 51.54 40.66
Support Level $86.10 $9.12
Resistance Level $94.48 $11.88
Average True Range (ATR) 3.75 0.92
MACD -0.58 0.04
Stochastic Oscillator 28.98 62.40

Price Performance

Historical Comparison
TRNS
OMER

About TRNS Transcat Inc.

Transcat Inc is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing services and products to high regulated industries, particularly the life sciences industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. It conducts business through two operating segments: Services and Distribution.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: